Evidence mapPaperPMID 40455233Full record

SynthesisNaunyn-Schmiedeberg's archives of pharmacology2025

The effect of flavonoids on the doxorubicin efficacy in cancer treatment.

Solmaz Asnaashari, Elham Amjad, Babak Sokouti

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Solmaz AsnaashariBiotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Elham AmjadStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. elham.amjad1996@gmail.com.
Babak SokoutiBiotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. b.sokouti@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although doxorubicin (DOX) chemotherapy is widely used to treat malignant tumors, its cardiotoxicity restricts its widespread use. Flavonoids may mitigate DOX-induced cardiotoxicity. A systematic review was conducted to determine whether flavonoids can prevent DOX-induced cardiotoxicity. Therefore, it would be interesting to examine the effects of flavonoids on DOX activity. Based on a Boolean query in the well-known Scopus database, we present our review of doxorubicin and flavonoids simultaneously as combination drugs for cancer treatment. Following the retrieval and review of the intended investigations based on the input keywords, the anticancer mechanisms of flavonoids and doxorubicin are discussed, along with their effects on different targets. Several apoptotic/pro-apoptotic proteins are induced through targeted signaling pathways, which may activate several caspases that cause apoptosis, leading to cell death. In this study, flavonoids differentially modulated the efficacy of doxorubicin chemotherapeutics by interfering with chemotherapy-induced apoptosis and cell cycle arrest. Based on this information, we were able to better understand how dietary agents may affect chemotherapy.

Indexed as

Antibiotics, AntineoplasticDoxorubicinFlavonoidsNeoplasmsAnimalsApoptosisCardiotoxicityHumansAntibiotics, AntineoplasticDoxorubicinFlavonoidsAnticancerDoxorubicinEffectFlavonoidTreatment

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.